Page 12 - Read Online

van Waardenburg et al. Cancer Drug Resist 2021;4:837-41 https://dx.doi.org/10.20517/cdr.2021.80 Page 5

analysis. Eur J Cancer 2021;149:134-52. DOI PubMed
5. Tutt ANJ, Garber JE, Kaufman B, et al; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for patients
with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384:2394-405. DOI PubMed
6. Carreira S, Porta N, Arce-Gallego S, et al. Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B
trial. Cancer Discov 2021. DOI PubMed
7. Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene
aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21:162-74. DOI PubMed PMC
8. Maughan BL, Antonarakis ES. Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate
cancer. Expert Opin Pharmacother 2021:1-8. DOI PubMed
9. Cleary JM, Wolpin BM, Dougan SK, et al. Opportunities for utilization of DNA repair inhibitors in homologous recombination repair-
deficient and proficient pancreatic adenocarcinoma. Clin Cancer Res 2021. DOI PubMed
10. Nickoloff JA, Taylor L, Sharma N, Kato TA. Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and
normal tissue protection in radiotherapy. Cancer Drug Resist 2021;4:244-63. DOI PubMed PMC
11. Gutierrez R, O’Connor TR. DNA direct reversal repair and alkylating agent drug resistance. Cancer Drug Resist 2021;4:414-23. DOI
12. Saliba AN, John AJ, Kaufmann SH. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. Cancer Drug
Resist 2021;4:125-42. DOI PubMed PMC
13. Lee KJ, Wright G, Bryant H, Wiggins LA, Schuler M, Gassman NR. EGFR signaling promotes resistance to CHK1 inhibitor
prexasertib in triple negative breast cancer. Cancer Drug Resist 2020;3:980-91. DOI
14. Zeng L, Beggs RR, Cooper TS, Weaver AN, Yang ES. Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro
and in vivo cytotoxicity in head and neck squamous cell carcinoma. Mol Cancer Ther 2017;16:591-600. DOI PubMed PMC
15. Yang ES, Deutsch E, Mehmet A, et al. A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally
advanced head and neck squamous cell carcinoma. Radiother Oncol 2021;157:203-9. DOI PubMed
16. Juhlin CC. Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising
through dedifferentiation: implications for future therapeutic algorithms? Cancer Drug Resist 2020;3:992-1000. DOI
17. Fabbrizi MR, Parsons JL. Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck
cancer treatment. Cancer Drug Resist 2020;3:775-790. DOI
18. Liu YL, Selenica P, Zhou Q, et al. BRCA mutations, homologous DNA repair deficiency, tumor mutational burden, and response to
immune checkpoint inhibition in recurrent ovarian cancer. JCO Precis Oncol 2020;4:665-79. DOI PubMed PMC
19. Morand S, Stanbery L, Walter A, Rocconi RP, Nemunaitis J. BRCA1/2 mutation status impact on autophagy and immune response:
unheralded target. JNCI Cancer Spectr 2020;4:pkaa077. DOI PubMed PMC
20. Peyraud F, Italiano A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers (Basel) 2020;12:1502.
DOI PubMed PMC